VBI Vaccines Inc (NASDAQ:VBIV) – Oppenheimer issued their FY2023 earnings per share estimates for shares of VBI Vaccines in a research report issued on Monday, August 12th. Oppenheimer analyst L. Gershell forecasts that the biopharmaceutical company will post earnings per share of ($0.21) for the year. Oppenheimer currently has a “Buy” rating and a $5.00 target price on the stock.
VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. The firm had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.60 million. VBI Vaccines had a negative net margin of 1,582.45% and a negative return on equity of 71.46%.
VBIV has been the topic of a number of other reports. ValuEngine upgraded shares of VBI Vaccines from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. BMO Capital Markets reduced their price target on shares of VBI Vaccines to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, June 18th. Finally, Zacks Investment Research upgraded shares of VBI Vaccines from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Thursday, May 9th.
Shares of NASDAQ VBIV opened at $0.62 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.94 and a current ratio of 1.99. The company has a market cap of $64.89 million, a P/E ratio of -0.64 and a beta of 0.41. The firm’s fifty day moving average is $0.82 and its two-hundred day moving average is $1.58. VBI Vaccines has a 52-week low of $0.57 and a 52-week high of $2.78.
In related news, CEO Jeff Baxter purchased 144,000 shares of VBI Vaccines stock in a transaction on Wednesday, June 19th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $105,120.00. Following the acquisition, the chief executive officer now owns 458,255 shares in the company, valued at approximately $334,526.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 1,000,000 shares of VBI Vaccines stock in a transaction on Monday, June 17th. The stock was bought at an average price of $0.62 per share, for a total transaction of $620,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 1,160,000 shares of company stock worth $739,600. 10.50% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new stake in shares of VBI Vaccines in the 2nd quarter worth about $25,000. Citadel Advisors LLC bought a new stake in shares of VBI Vaccines in the 2nd quarter worth about $31,000. Weil Company Inc. purchased a new position in shares of VBI Vaccines during the 1st quarter worth about $41,000. Massey Quick Simon & CO. LLC purchased a new position in shares of VBI Vaccines during the 1st quarter worth about $42,000. Finally, Bank of Montreal Can boosted its stake in shares of VBI Vaccines by 71.8% during the 2nd quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 15,717 shares during the period. Hedge funds and other institutional investors own 46.03% of the company’s stock.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Featured Article: What are momentum indicators and what do they show?
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.